Latest On Dechra Pharmaceuticals PLC (DPHAY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-13 14:37 EST | News | Dechra Pharmaceuticals jumps 45% after confirming EQT takeover talks | N/A |  |
| 2023-03-09 05:05 EST | Dividend | A dividend of $0.3 has been announced on Feb 27, 2023. It will be paid Apr 28, 2023 with an ex-dividend date of Mar 9, 2023. | Neutral | |
| 2022-10-27 06:04 EST | Dividend | A dividend of $0.74 has been announced on Oct 7, 2022. It will be paid Dec 5, 2022 with an ex-dividend date of Oct 27, 2022. | Neutral | |
| 2022-03-09 05:05 EST | Dividend | A dividend of $0.32 has been announced on Feb 28, 2022. It will be paid Apr 22, 2022 with an ex-dividend date of Mar 9, 2022. | Neutral | |
| 2022-02-22 15:35 EST | News | Dechra Pharmaceuticals PLC's (DPHAY) CEO Ian Page on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-02-22 15:35 EST | News | Dechra Pharmaceuticals PLC GAAP EPS of $0.37, revenue of $332.4M | N/A | |
| 2022-02-21 22:37 EST | News | Dechra Pharmaceuticals PLC 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-02-21 22:37 EST | News | Dechra Pharmaceuticals PLC (DPHAY) CEO Ian Page On Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2021-10-28 07:51 EST | Dividend | A dividend of $0.81 has been announced on Oct 19, 2021. It will be paid Dec 6, 2021 with an ex-dividend date of Oct 28, 2021. | Neutral | |
| 2021-03-05 05:08 EST | Dividend | A dividend of $0.32 has been announced on Feb 24, 2021. It will be paid Apr 22, 2021 with an ex-dividend date of Mar 5, 2021. | Neutral | |
| 2020-12-04 18:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 23:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-19 05:07 EST | Dividend | A dividend of $0.03 has been announced on N/A. It will be paid Nov 23, 2020 with an ex-dividend date of Nov 19, 2020. | Neutral | |
| 2020-11-08 02:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 05:04 EST | Dividend | A dividend of $0.59 has been announced on Oct 29, 2020. It will be paid Dec 10, 2020 with an ex-dividend date of Nov 6, 2020. | Neutral | |
| 2020-09-26 15:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 08:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-13 06:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-09 07:45 EST | News | Dechra: Hard To Justify The Valuation | N/A | |
| 2020-08-14 11:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 15:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 07:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 17:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 20:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 14:35 EST | News | Dechra Pharmaceuticals: Sell This Overvalued Share Today | N/A | |
| 2020-07-09 11:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 19:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 15:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 07:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 07:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 03:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 08:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 22:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 19:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 06:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-09 23:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-03 23:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-25 23:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-05 05:09 EST | Dividend | A dividend of $0.266181 has been announced on Feb 24, 2020. It will be paid Apr 23, 2020 with an ex-dividend date of Mar 5, 2020. | Neutral | |
| 2020-02-28 06:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 00:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 02:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 01:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-18 01:54 EST | Financials | Company financials have been released. | Neutral | |
About Dechra Pharmaceuticals PLC (DPHAY):
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
General
- Name Dechra Pharmaceuticals PLC
- Symbol DPHAY
- Type Common Stock
- Exchange OTCGREY
- Currency USD
- Country USA
- Full Time Employees 1,889
- Fiscal Year EndJune
- Web URLhttp://www.dechra.com
View More
Financials
- Most Recent Quarter 2020-06-30
- Profit Margin 7%
- Return on Assets 3%
- Return on Equity 6%
- Revenue Per Share $0
- Gross Profit 291.6 million
- Quarterly Earnings Growth 6.5%
View More
Highlights
- Market Capitalization 3.53 billion
View More
Share Statistics
- Shares Outstanding 102.31 million
- Shares Float 53.74 million
- % Held by Insiders <1%
View More
Technicals
- Beta 0.49
- 52 Week High $69.5
- 52 Week Low $69.5
- 50 Day Moving Average 69.5
- 200 Day Moving Average 69.5
View More
Dividends
- Dividend Date 2019-12-02
- ExDividend Date N/A
- Dividend Yield 0%
View More
Dechra Pharmaceuticals PLC (DPHAY) Dividend Calendar:
DPHAY's last dividend payment was made to shareholders on December 2, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Dechra Pharmaceuticals PLC (DPHAY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-03-31 | 2020-06-30 | $N/A | $0.12 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $124.25 million | $0.12 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $124.25 million | $0.08 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $125.2 million | $0.08 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $125.2 million | $0.10 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $115.7 million | $0.10 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $115.7 million | $0.10 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $78.17 million | $0.10 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $81.61 million | $0.06 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $0.06 | $0.00 | ||
| 2017-09-30 | 2017-12-31 | $0.19 | $0.00 | ||
| 2017-06-30 | 2017-09-30 | $0.19 | $0.00 | ||
| 2017-03-31 | 2017-06-30 | $0.11 | $0.00 | ||
| 2016-12-31 | 2017-03-31 | $0.11 | $0.00 | ||
| 2016-09-30 | 2016-12-31 | $0.07 | $0.00 | ||
| 2016-06-30 | 2016-09-30 | $0.07 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | $0.01 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | $0.01 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | $0.09 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.10 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | $0.08 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | $0.08 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $0.09 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $0.10 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $0.11 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.11 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.07 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.07 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.04 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $0.04 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.07 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.07 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.08 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.08 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.08 | $0.00 |
Dechra Pharmaceuticals PLC (DPHAY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | 8.25 million | 8.25 million | 8.25 million |
| Income Before Tax | N/A | N/A | 9.75 million | 9.75 million | 9.4 million |
| Selling General Administrative | N/A | N/A | 52.05 million | 52.05 million | 48.25 million |
| Gross Profit | N/A | N/A | 71.95 million | 71.95 million | 73.4 million |
| Ebit | N/A | N/A | 11.65 million | 11.65 million | 16.9 million |
| Operating Income | N/A | N/A | 11.65 million | 11.65 million | 16.9 million |
| Income Tax Expense | 350000 | 350000 | 3.15 million | 3.15 million | 1.7 million |
| Total Revenue | N/A | N/A | 124.25 million | 124.25 million | 125.2 million |
| Cost of Revenue | N/A | N/A | 52.3 million | 52.3 million | 51.8 million |
| Total Other Income Expense Net | N/A | N/A | -1.9 million | -1.9 million | -7.5 million |
| Net Income From Continuing Operations | N/A | N/A | 6.6 million | 6.6 million | 7.7 million |
| Net Income Applicable to Common Shares | 10.35 million | 10.35 million | 6.6 million | 6.6 million | 7.7 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -3.75 million | -3.75 million | N/A |
| Change to Liabilities | 4.65 million | 4.65 million | -4.6 million | -4.6 million | 4 million |
| Total Cash Flow from Investing Activities | -20.8 million | -20.8 million | -19.95 million | -19.95 million | -6.75 million |
| Net Borrowings | 12.2 million | 12.2 million | -1000000 | -1000000 | -4.75 million |
| Total Cash Flow from Financial Activities | N/A | N/A | -12.45 million | -12.45 million | -9.3 million |
| Change to Operating Activities | N/A | N/A | N/A | N/A | N/A |
| Change in Cash | N/A | N/A | -7.95 million | -7.95 million | -3.3 million |
| Total Cash from Operating Activities | 27.9 million | 27.9 million | 25.3 million | 25.3 million | 12.8 million |
| Depreciation | N/A | N/A | 3.4 million | 3.4 million | 8.25 million |
| Other Cash Flow from Investing Activities | 150000 | 150000 | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | -4.5 million | -4.5 million | -4.9 million |
| Change to Account Receivables | N/A | N/A | 7.45 million | 7.45 million | -10.7 million |
| Other Cash Flow from Financing Activities | -350000 | -350000 | -500000 | -500000 | N/A |
| Change to Net Income | -18.25 million | -18.25 million | 16.95 million | 16.95 million | -24.35 million |
| Capital Expenditures | N/A | N/A | 2.05 million | 2.05 million | 2.65 million |
Balance Sheet:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | 511.4 million | 511.4 million | 539.4 million |
| Total Stockholder Equity | N/A | N/A | 476.9 million | 476.9 million | 509.1 million |
| Other Current Liabilities | N/A | N/A | 23.7 million | 23.7 million | 23.3 million |
| Total Assets | N/A | N/A | 988.3 million | 988.3 million | 1.05 billion |
| Common Stock | 1.1 million | 1.1 million | 1000000 | 1000000 | 1000000 |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | 126.4 million | 126.4 million | 115.4 million | 115.4 million | 124.2 million |
| Other Liabilities | 112.4 million | 112.4 million | 101 million | 101 million | 114.4 million |
| Other Assets | 8.8 million | 8.8 million | 1000000 | 1000000 | 6.4 million |
| Cash | N/A | N/A | 64.4 million | 64.4 million | 80.3 million |
| Total Current Liabilities | N/A | N/A | 278.4 million | 278.4 million | 118.1 million |
| Other Stockholder Equity | 100.7 million | 100.7 million | 81.8 million | 81.8 million | 106 million |
| Property, Plant & Equipment | 76.4 million | 76.4 million | 70.7 million | 70.7 million | 58.4 million |
| Total Current Assets | N/A | N/A | 260.9 million | 260.9 million | 292.1 million |
| Long Term Investments | N/A | N/A | 16.7 million | 16.7 million | 10.1 million |
| Net Tangible Assets | -48.6 million | -48.6 million | -162.1 million | -162.1 million | -172.4 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | 122.9 million | 122.9 million | 306.9 million |
| Inventory | N/A | N/A | 108.8 million | 108.8 million | 104 million |
| Accounts Payable | N/A | N/A | 81.5 million | 81.5 million | 31.9 million |
Dechra Pharmaceuticals PLC (DPHAY) Chart:
Dechra Pharmaceuticals PLC (DPHAY) News:
Below you will find a list of latest news for Dechra Pharmaceuticals PLC (DPHAY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Dechra Pharmaceuticals PLC (DPHAY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Dechra Pharmaceuticals PLC (DPHAY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|